Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.

@article{Wang2015LongtermFO,
  title={Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.},
  author={Michael L. Wang and K. Blum and Peter Martin and A. Goy and R. Auer and B. Kahl and W. Jurczak and R. Advani and J. Romaguera and Michael E. Williams and J. Barrientos and E. Chmielowska and J. Radford and S. Stilgenbauer and M. Dreyling and W. Jędrzejczak and P. Johnson and S. Spurgeon and L. Zhang and L. Baher and M. Cheng and Dana Lee and D. Beaupre and S. Rule},
  journal={Blood},
  year={2015},
  volume={126 6},
  pages={
          739-45
        }
}
Ibrutinib, an oral inhibitor of Bruton tyrosine kinase, is approved for patients with mantle cell lymphoma (MCL) who have received one prior therapy. We report the updated safety and efficacy results from the multicenter, open-label phase 2 registration trial of ibrutinib (median 26.7-month follow-up). Patients (N = 111) received oral ibrutinib 560 mg once daily, and those with stable disease or better could enter a long-term extension study. The primary end point was overall response rate (ORR… Expand
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.
Long‐term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 18 REFERENCES
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
  • R. Fisher, S. Bernstein, +12 authors A. Goy
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.
  • A. Goy, R. Sinha, +7 authors T. Witzig
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
Is there an increased rate of additional malignancies in patients with mantle cell lymphoma?
Current treatment standards and emerging strategies in mantle cell lymphoma.
How to manage mantle cell lymphoma
Revised response criteria for malignant lymphoma.
  • B. Cheson, B. Pfistner, +17 authors V. Diehl
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
...
1
2
...